ArticleThe Journal of experimental medicine2011
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.
Article in The Journal of experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02021422 (A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients), which is not on this map. Cited by 144 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients
Who cites it
144 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.
- The associations between immunity-related genes and breast cancer prognosis in Korean women.PloS one · 2014Pooled it
- IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.Cancer research · 2018Trial
- Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese Han population.PloS one · 2012Trial
- A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.Breast cancer research : BCR · 2026Article
- Endometriosis immune microenvironment timing shifts: from immune escape to immune exhaustion.Cell death discovery · 2026Review
- CpG island demethylation and recruitment of SP1 to the promoter region regulates human thymic stromal lymphopoietin expression.Epigenetics · 2025Article
- Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study.Oncology letters · 2025Article
- Type 2 immunity in allergic diseases.Cellular & molecular immunology · 2025Review
- TSLP: contrasting roles in cancer.Frontiers in immunology · 2025Review
- Cutaneous T cell lymphoma atlas reveals malignant TNature immunology · 2024Article
- Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.Molecular cancer · 2024Review
- Roles of naïve CD4Journal of translational medicine · 2024Article
- Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential.Antibody therapeutics · 2024Article
- TSLP enhances progestin response in endometrial cancer via androgen receptor signal pathway.British journal of cancer · 2024Article
- Review
- JAK1 Is a Novel Target of Tumor- and Invasion-Suppressive microRNA 494-5p in Colorectal Cancer.Cancers · 2023Article
- Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis.Cancers · 2023Review
- Epstein‑Barr virus as a promoter of tumorigenesis in the tumor microenvironment of breast cancer (Review).International journal of molecular medicine · 2023Review
- Newly developed 3D in vitro models to study tumor-immune interaction.Journal of experimental & clinical cancer research : CR · 2023Review
- Role of thymic stromal lymphopoietin in allergy and beyond.Nature reviews. Immunology · 2023Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
The human breast tumor microenvironment can display features of T helper type 2 (Th2) inflammation, and Th2 inflammation can promote tumor development. However, the molecular and cellular mechanisms contributing to Th2 inflammation in breast tumors remain unclear. Here, we show that human breast cancer cells produce thymic stromal lymphopoietin (TSLP). Breast tumor supernatants, in a TSLP-dependent manner, induce expression of OX40L on dendritic cells (DCs). OX40L(+) DCs are found in primary breast tumor infiltrates. OX40L(+) DCs drive development of inflammatory Th2 cells producing interleukin-13 and tumor necrosis factor in vitro. Antibodies neutralizing TSLP or OX40L inhibit breast tumor growth and interleukin-13 production in a xenograft model. Thus, breast cancer cell-derived TSLP contributes to the inflammatory Th2 microenvironment conducive to breast tumor development by inducing OX40L expression on DCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.